Therefore, depleting BACH1 using either shRNA or a non-toxic inhibitor hemin could elicit the lactate dependency of cancer cells, increase the efficacy of MCT1 inhibitors, and suggest better therapeutic options for those with TNBC. The gene discussed is BACH1; the disease is cancer.